Goldman Sachs Reiterates Buy Rating on Moderna (MRNA), 'Additional neoantigen therapy data at ASCO is an incremental positive'
Tweet Send to a Friend
Goldman Sachs analyst Salveen Richter reiterated a Buy rating and $299.00 price target on Moderna (NASDAQ: MRNA)."At the American Society ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
